7 Scleroderma Headlines

admin avatar

by admin |

Share this article:

Share article via email

1 – 8 Scleroderma-Related Conditions You Should Look Out For

news_11_Artboard 343 copy 22

Learn more about these eight scleroderma-related conditions you should look out for.

Read full article: http://bit.ly/1UWD0yA


2 – Scleroderma Education Project, Delves into Organ Involvement in Recent Post

news_11_Artboard 343 copy 56

In July 2014, Edward Harris launched a website called the Scleroderma Education Project, where he writes and publishes articles providing comprehensive, unbiased, and research-based information about scleroderma. His articles are crafted to an audiences’ varied concerns — including a March 8 post on organ involvement in the disease — and his education project is now a trusted source of information about scleroderma, recording visits from more than 12,500 patients in 115 countries in the past six months alone.

Read full article here: http://bit.ly/1Tg5ymV

3 – 10 Things to Care for in Scleroderma


Learn more about ten things to care for in scleroderma.

Read full article here: http://bit.ly/1UWFxJl

4 – Clinical Trial Notification Program for Scleroderma Patients

news_11_Artboard 343 copy 37

Many readers of Scleroderma News have reached out and urged us to do more to bring additional awareness about clinical trials applicable to the scleroderma patient community.

Read full article here: http://bit.ly/1YaKCwT

5 – 6 Types Of Scleroderma

news_11_Artboard 343 copy 43

According to the Scleroderma Foundation, scleroderma is a chronic systemic autoimmune disease characterised by hardening (sclero) of the skin (derma), it may also affect other organs. There is still no cure for scleroderma but effective treatments for some forms of the disease are available.

Read full article here: http://bit.ly/1YaLjWX

6 – New Cannabinoid-based Drug Slows Fibrosis, Blocks Inflammation in Early Scleroderma Study

news_12_scleroderma copy

A research team has developed a cannabinoid-based drug which stimulates not only one, but two, receptors believed to be involved in fibrosis development in scleroderma. The drug, VCE-004.8, prevented the formation of fibrosis-promoting myofibroblasts in culture and stopped fibrotic changes in a mouse model of dermal fibrosis. Findings from these pre-clinical studies, while early, are promising and may lead to a new therapy for SSc.

Read full article here: http://bit.ly/1RnyvuL

7 – AUTOIMMUNE AWARENESS MONTH: Spotlight on Ssc Patient Wyatt Wright

news_11_Artboard 343 copy 57

Wyatt Wright a.k.a (Wyatt The Warrior) is a 9-year-old young man who was diagnosed with localized scleroderma (linear) at the age of 8.

Read full article here: http://bit.ly/1TkPeBj